 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Postdoctoral Fellow, Departments of Pharmacy Practice and Family Medicine, University of Florida, Gainesville, FL
Professor of Pharmacy and Medicine; Director of Clinical Research in Family Medicine, Departments of Pharmacy Practice and Family Medicine, University of Florida
Reprints: Dr. Anderson, Family Medicine on 4th Ave., 625 SW 4th Ave., Gainesville, FL 32601, fax 352/392-7766, sda2{at}ufl.edu
OBJECTIVE: To summarize and evaluate the literature concerning ceftobiprole.
DATA SOURCES: Literature identification was conducted through MEDLINE (1966–February 2008) and International Pharmaceutical Abstracts (1970–February 2008) using the terms ceftobiprole, medocaril, BAL 5788, RO-5788, BAL 9141, RO 63-9141, pyrrolidinone cephalosporin, MRSA, complicated skin and skin-structure infections (cSSSIs), community-acquired pneumonia, and nosocomial pneumonia. Additional publications were identified through a review of articles and abstracts from infectious disease meetings.
STUDY SELECTION AND DATA EXTRACTION: All articles in English were evaluated and all pertinent information was included.
DATA SYNTHESIS: Ceftobiprole medocaril is an extended-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus spp., vancomycin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus faecalis, Enterobacteriaceae, and Pseudomonas aeruginosa. Inactivity includes extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae and Enterococcus faecium. Preliminary data suggest that ceftobiprole may be effective with a 1-hour infusion of 500 mg every 12 hours for gram-positive infections and 500 mg every 8 hours with a 2-hour infusion for polymicrobial infections. Two clinical trials support these dosing regimens for cSSSIs. Ceftobiprole was noninferior to vancomycin in suspected gram-positive cSSSIs, with cure rates of 93.3% and 93.5%, respectively. Furthermore, ceftobiprole was noninferior to vancomycin and ceftazidime in polymicrobial cSSSIs (cure rates 90.5% vs 90.2%, respectively). Although the total number of adverse effects was similar to those of the comparator, more patients in the ceftobiprole group experienced nausea, vomiting, and dysgeusia.
CONCLUSIONS: The activity of ceftobiprole and limited clinical data suggest that it may be useful as empiric monotherapy for cSSSI and in combination with other antimicrobials in lower respiratory tract infections for which Phase 3 clinical trials are currently exploring. Although not shown in vitro, ceftobiprole may induce resistance due to its broad spectrum of activity. Approval is expected for the treatment of cSSSI.
Key Words: ceftobiprole, cephalosporin, community-acquired pneumonia, complicated skin and skin-structure infections, medocaril, methicillin-resistant Staphylococcus aureus, nosocomial pneumonia, pyrrolidinone
Published Online, May 13, 2008. www.theannals.com, DOI 10.1345/aph.1L016
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-08-010-H01-P
This article has been cited by other articles:
|
|
 |
|
  S. M. Drawz and R. A. Bonomo Three Decades of {beta}-Lactamase Inhibitors Clin. Microbiol. Rev., January 1, 2010; 23(1): 160 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. I. Llarrull, J. F. Fisher, and S. Mobashery Molecular Basis and Phenotype of Methicillin Resistance in Staphylococcus aureus and Insights into New {beta}-Lactams That Meet the Challenge Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4051 - 4063. [Full Text] [PDF]
|
|
|
|
|
|
S. Lemaire, Y. Glupczynski, V. Duval, B. Joris, P. M. Tulkens, and F. Van Bambeke Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1 Macrophages and Keratinocytes) Forms of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2289 - 2297. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
